Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / VRTX
Stock rating · Pharmaceutical Preparations
Vertex Pharmaceuticals Inc (VRTX) Stock Rating & Analysis
As of October 7, 2026, MELANY rates Vertex Pharmaceuticals Inc 64 out of 100 (Hold). Its highest factor scores are business quality and catalyst setup at 83, and its lowest is valuation at 38.
MELANY ratingRated 2026-10-07VRTX · composite score
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for serious diseases. Its main products are the cystic fibrosis therapies Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek, where its treatments remain the global standard of care. It has broadened its portfolio with Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid medication for moderate-to-severe acute pain in adults.
Rating as of 2026-10-07 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
How VRTX's rating has moved
- +2Past week, since Sep 30: no longer flagged Runner!, now Hold, score rose 2 points to 64.
- +5Past four weeks, since Sep 9: Very Promising to Hold, score rose 5 points to 64.
Weekly points: Sep 9: 59 · Sep 16: 60 · Sep 23: 61 · Sep 30: 62 · Oct 7: 64 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why VRTX scores 64/100
VRTX's 8 factor scores run from 38 to 83, and 4 of them sit above its composite of 64. Here is how VRTX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 55%
- ROE 24%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Earnings in 27 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 27 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How VRTX compares
As of October 7, 2026, Vertex Pharmaceuticals Inc is tied for 11th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Also ranked in Healthcare Stocks. All stock rating pages.
Key risks for VRTX
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Vertex Pharmaceuticals Inc sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 61/100 for strength. Theme strength feeds VRTX's momentum and catalyst factors above.
Tracking VRTX
Vertex Pharmaceuticals Inc rates Hold right now, so MELANY is not flagging a fresh entry. Add VRTX to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates VRTX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Vertex Pharmaceuticals Inc's 64/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about VRTX
Is Vertex Pharmaceuticals Inc (VRTX) a buy?
As of 2026-10-07, MELANY rated Vertex Pharmaceuticals Inc Hold with a composite score of 64/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Vertex Pharmaceuticals Inc's MELANY score?
Vertex Pharmaceuticals Inc (VRTX) has a MELANY composite score of 64/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the VRTX stock rating calculated?
MELANY scores VRTX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Vertex Pharmaceuticals Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Vertex Pharmaceuticals Inc (VRTX) Hold with a composite of 64/100 as of 2026-10-07. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the VRTX stock price forecast?
MELANY does not publish price targets or forecasts for VRTX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 64/100 across eight factors for Vertex Pharmaceuticals Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is VRTX stock overvalued or undervalued?
MELANY's valuation factor currently reads 38/100 for Vertex Pharmaceuticals Inc, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives VRTX's read.
What price should I buy VRTX at?
MELANY is not flagging a fresh entry for VRTX at its current Hold rating, so there is no entry zone to publish right now. Add VRTX to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying VRTX stock?
The top risks MELANY currently flags for Vertex Pharmaceuticals Inc: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Vertex Pharmaceuticals Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 83/100 for Vertex Pharmaceuticals Inc, and earnings track record, at 63/100. The 64/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will VRTX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 65/100 for VRTX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this VRTX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-07. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores VRTX continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, VRTX included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.